Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8933 results

  1. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

    Quality standard
    In development

  2. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development Reference number: GID-TA10393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development Reference number: GID-TA10431 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

    Awaiting development Reference number: GID-TA11088 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Awaiting development Reference number: GID-TA11276 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]

    Awaiting development Reference number: GID-TA10198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]

    Awaiting development Reference number: GID-TA11076 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]

    Awaiting development Reference number: GID-TA11222 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development